AFR Winner

Employees: 100-499

OxaliTEX is a first-in-class oncology drug candidate developed to treat ovarian cancer patients resistant to platinum with minimal severe toxic side effects. This represents a life-changing potential impact for more than 239,000 women diagnosed with ovarian cancer and the 80-90% of those who will develop platinum resistance.